Lifestyle Modification and Incretin-Based Therapy for Obesity
Authors:
Top Cited Papers
- 23 June 2026
- journal article
- Published by American Medical Association (AMA) in JAMA
- Vol. 335 (24) , 2160
Abstract
This JAMA Insights discusses strategies for lifestyle modifications and managing adverse effects for individuals with obesity receiving incretin-based therapies for weight loss.Keywords
This publication has 10 references indexed in Scilit:
- Managing Adverse Effects of Incretin-Based Medications for ObesityJAMA, 2025
- Tirzepatide as Compared with Semaglutide for the Treatment of ObesityNew England Journal of Medicine, 2025
- Real‐world insights into incretin‐based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross‐sectional studyDiabetes, Obesity and Metabolism, 2025
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity SocietyThe American Journal of Clinical Nutrition, 2025
- Evolving Approaches for Pharmacological Therapy of ObesityAnnual Review of Pharmacology and Toxicology, 2025
- Physical Activity and Excess Body Weight and Adiposity for Adults. American College of Sports Medicine Consensus StatementMedicine & Science in Sports & Exercise, 2024
- Medications for ObesityJAMA, 2024
- Enhanced protein intake on maintaining muscle mass, strength, and physical function in adults with overweight/obesity: A systematic review and meta-analysisClinical Nutrition ESPEN, 2024
- The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical OpportunitiesCurrent Obesity Reports, 2023
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in AdultsJACC, 2014